AnaptysBio (NASDAQ:ANAB) Earns “Buy” Rating from HC Wainwright

AnaptysBio (NASDAQ:ANAB)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $66.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 19.00% from the company’s current price.

Several other equities analysts also recently commented on the stock. Wedbush boosted their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. UBS Group upped their price target on AnaptysBio from $70.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Finally, Barclays increased their price target on AnaptysBio from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, March 4th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $80.10.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $55.46 on Monday. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -106.65 and a beta of 0.32. The firm has a 50 day simple moving average of $55.67 and a 200-day simple moving average of $44.24. AnaptysBio has a one year low of $15.40 and a one year high of $68.39.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. Equities analysts predict that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a share buyback plan on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In related news, insider Paul F. Lizzul sold 3,650 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $163,191.50. Following the completion of the transaction, the insider owned 42,088 shares in the company, valued at approximately $1,881,754.48. The trade was a 7.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Magda Marquet sold 11,000 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $48.23, for a total value of $530,530.00. Following the completion of the transaction, the director directly owned 9,930 shares in the company, valued at $478,923.90. This trade represents a 52.56% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 110,193 shares of company stock worth $5,333,138. 33.50% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of AnaptysBio by 940.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 1,383 shares during the last quarter. Invesco Ltd. grew its stake in AnaptysBio by 192.6% during the 4th quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock worth $6,012,000 after buying an additional 81,625 shares during the last quarter. Mackenzie Financial Corp acquired a new position in AnaptysBio during the fourth quarter worth approximately $1,166,000. XTX Topco Ltd increased its position in AnaptysBio by 113.3% during the fourth quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock worth $1,873,000 after buying an additional 20,526 shares during the period. Finally, nVerses Capital LLC purchased a new stake in AnaptysBio in the fourth quarter valued at approximately $215,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.